This report marks a pivotal transition for Replimune Group, a clinical-stage biotechnology company that is now becoming a commercial enterprise. The fiscal second quarter was the first full period following the U.S. Food and Drug Administration (FDA) accelerated approval of TUDRIQEV for certain patients with advanced melanoma. Because the company operates on a March fiscal year, this quarter ended September 30, 2026, falls within its fiscal 2027. With first commercial shipments beginning in early October, investors are watching closely to see whether early launch traction and disciplined spending translate into a sustainable commercial ramp. The results also offer an early read on how the company is managing costs while scaling its sales force and manufacturing capabilities. I checked a few comparable names in the sector using Tickeron’s AI Screener to get a sense of how Replimune stacks up on key metrics.
Replimune Group reported a net loss of $57.1 million, or $0.54 per basic and diluted share, for its fiscal second quarter ended September 30, 2026. That compares with a net loss of $83.1 million in the prior-year period. The result came in ahead of the analyst consensus estimate, which called for a loss of approximately $0.78 per share.
The company did not record product revenue during the quarter, as its first commercial shipments of TUDRIQEV occurred in early October. Management indicated it expects to report initial product revenue in the fiscal third quarter but is not providing formal revenue guidance.
On the cost side, R&D expense was $34.4 million, down from $57.9 million a year earlier. SG&A expense was $21.9 million, down from $26.4 million, though the figure reflects increased investment tied to commercial launch readiness, field hiring, and patient support programs. Replimune ended the period with $307.8 million in cash and cash equivalents, including roughly $141 million in net proceeds from an August 2026 equity offering. From what I see, the cash position provides a solid runway as the company moves into this new phase.
Replimune shares rose sharply following the release, gaining about 12.6% to reach roughly $14.70 as investors responded to the narrower-than-expected loss and early launch commentary. Sentiment has been building since the August accelerated approval of TUDRIQEV, which shifted the narrative from clinical development to commercial execution. Management reported that TUDRIQEV was first delivered to patients on October 6, with more than 15 institutions prescribing the therapy within the initial weeks. Analysts remain focused on the pace of adoption, reimbursement dynamics, and how early orders convert into recognized revenue. The market's reaction suggests investors are encouraged by the combination of a leaner cost structure and a commercial launch that is now underway.
Looking ahead, the primary focus shifts to the commercial trajectory of TUDRIQEV and how quickly initial prescribing institutions convert into repeat orders. Management highlighted a target of roughly 200 priority accounts and noted that interest is extending beyond academic centers into community practices, with more than 50 meetings held with melanoma treaters to date.
Investors should monitor early adoption metrics, including the number of accounts ordering, the pace of patient starts, and reimbursement progress. Because TUDRIQEV's revenue may be recognized over multiple quarters in some cases, reported top-line figures could lag underlying demand signals in the near term.
On the clinical front, the company continues to enroll IGNYTE-3, the Phase 3 confirmatory study of TUDRIQEV plus nivolumab, and the REVEAL study in uveal melanoma. Cost discipline will also remain in focus, given the ongoing investments in the commercial launch and clinical programs. With a cash runway of more than 12 months, the company has time to demonstrate execution, but the pace of spending relative to early revenue recognition will be a key metric for investors to watch. I’m watching this closely as the launch data starts to come in.
In my view, tools like Tickeron’s AI Screener can be helpful when evaluating names in the biotechnology space. The platform lets users apply filters for technical patterns, fundamentals, trends, and AI-driven signals across thousands of stocks and ETFs. It supports customizable scans by industry, market cap, volatility, and performance metrics, which can surface comparable opportunities or help refine a watchlist. For someone following Replimune Group, it offers one way to put the company’s metrics in context with peers without manual effort. I’ve found it useful for quick checks on sector trends and breakout candidates when building out research notes.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where REPL declined for three days, in 258 of 306 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.
The 10-day RSI Indicator for REPL moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 19 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on REPL as a result. In 67 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for REPL turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 39 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 183 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 175 of 218 cases where REPL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.282) is normal, around the industry mean (3.596). P/E Ratio (-6.863) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of oncolytic immunotherapies
Industry Biotechnology